Market Overview

Aegis Capital Reiterates Buy Rating on Amarin Following Reports of Positive Statin-Vascepa Combo


In a report published on Friday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating and a price target of $35 on Amarin (NASDAQ: AMRN).

In the report, Aegis Capital stated, "This morning, Amarin reported positive data from a Phase 1 clinical trial assessing the pharmacokinetic profile of a fixed-dose combination of the firm's flagship drug product, Vascepa (icosapent ethyl) and a statin (in this case, Crestor or rosuvastatin). This data represents a key cornerstone of Amarin's long- term strategy to eke out a solid market position in the cardiovascular space."

Amarin closed on Thursday at $6.30.

Latest Ratings for AMRN

Oct 2019Initiates Coverage OnBuy
Oct 2019Initiates Coverage OnNeutral
Mar 2019Initiates Coverage OnBuy

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Aegis Capital Raghuram SelvarajuAnalyst Color Reiteration Analyst Ratings


Related Articles (AMRN)

View Comments and Join the Discussion!

Latest Ratings

TGTXCantor FitzgeraldMaintains19.0
SPLKCleveland ResearchDowngrades
IQVWolfe ResearchUpgrades
PRAHWolfe ResearchUpgrades
DEBank of AmericaDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Reverse Mergers: Scam or Ultimate Value Buy?

VIDEO: Tesla Unveils a Demonstration of the Battery Swapping Technology in the Model S (TSLA)